In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19.
Sacramento CQ, Fintelman-Rodrigues N, Temerozo JR, Da Silva APD, Dias SDSG, da Silva CDS, Ferreira AC, Mattos M, Pão CRR, de Freitas CS, Soares VC, Hoelz LVB, Fernandes TVA, Branco FSC, Bastos MM, Boechat N, Saraiva FB, Ferreira MA, Jockusch S, Wang X, Tao C, Chien M, Xie W, Patel D, Garzia A, Tuschl T, Russo JJ, Rajoli RKR, Pedrosa CSG, Vitória G, Souza LRQ, Goto-Silva L, Guimarães MZ, Rehen SK, Owen A, Bozza FA, Bou-Habib DC, Ju J, Bozza PT, Souza TML.
Sacramento CQ, et al. Among authors: tao c.
J Antimicrob Chemother. 2021 Jun 18;76(7):1874-1885. doi: 10.1093/jac/dkab072.
J Antimicrob Chemother. 2021.
PMID: 33880524
Free PMC article.